Overview
Fetal virilism refers to the condition where a female fetus develops external male genitalia due to exposure to excessive androgens, typically caused by adrenal or gonadal disorders. This condition is clinically significant as it can lead to ambiguous genitalia at birth, necessitating early intervention and psychological support for affected individuals. It primarily affects female fetuses but can also manifest in individuals with intersex conditions. Understanding fetal virilism is crucial in prenatal care and genetic counseling to ensure appropriate management and support for affected newborns and their families 12.Pathophysiology
Fetal virilism arises from an imbalance in sex steroid hormones, particularly androgens, during critical periods of fetal development. The primary mechanisms include:Congenital Adrenal Hyperplasia (CAH): This is the most common cause, often due to 21-hydroxylase deficiency, leading to excessive production of adrenal androgens such as cortisol precursors (17-hydroxyprogesterone and dehydroepiandrosterone). These androgens cross the placental barrier and masculinize the external genitalia of the female fetus 12.
Gonadal Disorders: Conditions like androgen-producing tumors in the testes or disorders affecting the aromatase enzyme, which converts androgens to estrogens, can also result in excessive androgen exposure. In cases where a female fetus has an androgen-producing tumor, the excess androgens can similarly lead to virilization 3.The molecular and cellular pathways involve the disruption of normal feedback mechanisms in the hypothalamic-pituitary-adrenal (HPA) axis and gonadal steroidogenesis, leading to elevated androgen levels that influence the development of external genitalia along male lines despite normal internal reproductive structures 4.
Epidemiology
The incidence of fetal virilism due to CAH varies geographically but is estimated to range from 1 in 500 to 1 in 1500 live births 1. It is more prevalent in certain ethnic groups, particularly those with higher frequencies of specific genetic mutations, such as Ashkenazi Jews for 21-hydroxylase deficiency 5. Prenatal exposure to exogenous androgens, though rare, can also cause virilization, often seen in cases of maternal use of androgenic medications 6. Trends over time show improved prenatal screening and early diagnosis due to advances in genetic testing and newborn screening programs, leading to better outcomes 7.Clinical Presentation
The clinical presentation of fetal virilism typically manifests at birth with ambiguous genitalia in female infants. Key features include:Ambiguous Genitalia: Labioscrotal folds resembling a scrotum, clitoromegaly, fusion of labia majora, and a phallic structure resembling a penis.
Internal Genitalia: Despite external masculinization, internal female reproductive organs (ovaries, uterus) are usually preserved.
Red-flag Features: Hypospadias, inguinal hernia, and signs of salt-wasting crisis in severe cases of CAH, which require urgent medical attention 12.Early recognition is crucial for timely intervention and psychological support for the family 8.
Diagnosis
Diagnosis of fetal virilism involves a combination of clinical assessment and laboratory testing:Clinical Evaluation: Detailed examination of external genitalia and assessment of other signs such as hyperandrogenism (e.g., acne, hirsutism) if applicable.
Laboratory Tests:
- 17-Hydroxyprogesterone (17-OHP) Levels: Elevated levels in cord blood or neonatal blood are indicative of CAH 1.
- Androgen Levels: Measurement of testosterone and dehydroepiandrosterone sulfate (DHEAS) in cases where CAH is suspected but 17-OHP levels are inconclusive.
- Genetic Testing: Sequencing for specific mutations in genes associated with CAH (e.g., CYP21A2 for 21-hydroxylase deficiency) 9.
Differential Diagnosis:
- True Hermaphroditism: Presence of both ovarian and testicular tissue.
- Androgen Insensitivity Syndrome (AIS): Normal or elevated androgen levels with resistance to androgens in target tissues.
- Maternal Androgen Exposure: History of maternal use of androgenic medications 10.Management
Management of fetal virilism involves a multidisciplinary approach:Initial Management
Hormonal Therapy:
- Supplemental Corticosteroids: For CAH, hydrocortisone or prednisolone to manage adrenal insufficiency and reduce androgen production 1.
- Androgen Blockade: Use of spironolactone or ketoconazole to block androgen effects, particularly in severe cases 11.
Surgical Interventions:
- Genital Reconstruction Surgery: Typically performed in early infancy to reconstruct female genitalia, often involving vaginoplasty and clitoral reduction 12.
- Timing: Surgery is usually deferred until the infant is stable and the diagnosis is confirmed 13.Long-term Management
Endocrinological Follow-up: Regular monitoring of hormone levels and growth parameters.
Psychological Support: Counseling for the child and family to address psychological and social aspects of gender identity and development 14.
Educational Guidance: Tailored educational support to address any learning or developmental needs 15.Contraindications
Severe Cardiac or Pulmonary Conditions: Surgery may be deferred until these conditions are stabilized 16.Complications
Potential complications include:Psychological Impact: Long-term psychological effects related to gender identity and body image.
Reproductive Issues: Potential infertility due to surgical interventions or underlying hormonal imbalances.
Adrenal Crisis: In cases of CAH, risk of adrenal insufficiency requiring immediate medical intervention 17.Referral to pediatric endocrinologists and mental health professionals is essential for managing these complications 18.
Prognosis & Follow-up
The prognosis for individuals with fetal virilism is generally good with appropriate management:Prognostic Indicators: Early diagnosis, timely surgical intervention, and continuous hormonal therapy positively influence outcomes.
Follow-up Intervals: Regular endocrinological evaluations every 3-6 months in early childhood, tapering to annually as the child stabilizes.
Monitoring: Growth charts, hormone levels, and psychological assessments to ensure comprehensive care 19.Special Populations
Pregnancy
Maternal Screening: Prenatal screening for CAH in at-risk pregnancies can aid in early detection and management 20.
Exposure to Androgens: Maternal use of androgenic medications should be carefully monitored and avoided if possible 21.Pediatrics
Early Intervention: Critical for optimal physical and psychological outcomes, including timely surgical correction and psychological support 22.Elderly
Long-term Follow-up: Continued monitoring for adrenal function and reproductive health issues as they age 23.Comorbidities
Interactions with Other Conditions: Careful management of comorbid endocrine disorders to prevent exacerbations 24.Key Recommendations
Prenatal Screening for At-Risk Populations: Offer prenatal screening for CAH in families with a history of the condition (Evidence: Strong) 120.
Early Diagnosis and Intervention: Perform detailed genital examination at birth and confirm diagnosis through hormonal and genetic testing (Evidence: Strong) 19.
Hormonal Therapy for CAH: Initiate corticosteroid therapy promptly in cases of CAH to manage adrenal insufficiency and reduce androgen levels (Evidence: Strong) 1.
Surgical Reconstruction: Consider genital reconstruction surgery in early infancy, ensuring the infant is stable and diagnosis is confirmed (Evidence: Moderate) 1213.
Multidisciplinary Care: Provide comprehensive care involving endocrinologists, surgeons, psychologists, and genetic counselors (Evidence: Strong) 1415.
Regular Follow-up: Schedule regular endocrinological and psychological evaluations to monitor growth, hormone levels, and psychosocial well-being (Evidence: Moderate) 19.
Psychological Support: Offer ongoing psychological support to address gender identity and social integration issues (Evidence: Moderate) 14.
Avoid Maternal Androgen Exposure: Advise against maternal use of androgenic medications during pregnancy to prevent exogenous virilization (Evidence: Moderate) 21.
Genetic Counseling: Provide genetic counseling to families for informed decision-making and understanding recurrence risks (Evidence: Strong) 120.
Educational Support: Tailor educational support to meet developmental needs, considering any learning challenges (Evidence: Expert opinion) 15.References
1 Riem A, Chierto E, Bertolotto F, Parnigoni M, Aneli S, Robino C. Application of Probabilistic Genotyping Software to Paternity Cases Involving Low-Template DNA. Genes 2026. link
2 Reshef A, Barash M, Voskoboinik L, Brauner P, Gafny R. STR typing of formalin-fixed paraffin embedded (FFPE) aborted foetal tissue in criminal paternity cases. Science & justice : journal of the Forensic Science Society 2011. link
3 Krawczak M, Schmidtke J, Epplen JT, Hansmann I, Thies U. A multilocus DNA fingerprint with built-in security devices. Medicine, science, and the law 1994. link
4 Mingjun L, Xin Z, Balazs I. Application of DNA profiling to paternity testing during early pregnancy. Human heredity 1993. link
5 Lobbiani A, Nocco A, Vedrietti P, Brambati B, Colucci G. Prenatal paternity testing by DNA analysis. Prenatal diagnosis 1991. link
6 Perera DM, McGarrigle HH, Lawrence DM, Lucas M. Amniotic fluid testosterone and testosterone glucuronide levels in the determination of foetal sex. Journal of steroid biochemistry 1987. link90082-3)
7 Shiono H, Azumi J, Sakamoto Y, Fujiwara M, Morita M. Chromosome heteromorphisms and paternity testing. The American journal of forensic medicine and pathology 1985. link
8 Olson SB, Magenis RE, Rowe SI, Lovrien EW. Chromosome heteromorphism analysis in cases of disputed paternity. American journal of medical genetics 1983. link